Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The BD Onclarity HPV assay on SurePath collected samples meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Multicenter evaluation of the QIAstat-Dx respiratory panel for detection of viruses and bacteria in nasopharyngeal swab specimens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Update from a twelve-year nationwide fungaemia surveillance: increasing intrinsic and acquired resistance causes concern

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. PREVALENCE OF HUMAN PAPILLOMAVIRUS IN SELF-TAKEN SAMPLES FROM SCREENING NON-ATTENDERS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dientamoeba fragilis - a Commensal in Children in Danish Day Care Centers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Differential detection of Human Papillomavirus genotypes and cervical intraepithelial neoplasia by four commercial assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

This study describes a validation of the BD Onclarity HPV (Onclarity) assay using the international guidelines for HPV test requirements for cervical cancer screening of women 30 years and above using Danish SurePath screening samples. The clinical specificity (0.90, 95% CI: 0.88-0.91) and sensitivity (0.97, 95% CI: 0.87-1.0) of the Onclarity assay were shown to be non-inferior to the reference assay (specificity 0.90, 95% CI: 0.88-0.92, sensitivity 0.98, 95% CI: 0.91-1.0). The intra-laboratory reproducibility of Onclarity was 97% with a lower confidence bound of 96% (kappa value: 0.93). The inter laboratory agreement was 97% with lower confidence bound of 95% (kappa value: 0.92). The BD Onclarity HPV assay fulfills all the international guidelines for a new HPV test to be used in primarily screening. This is the first clinical validation of a new HPV assay using SurePath screening samples and thus the Onclarity HPV assay is the first HPV assay to hold an international validation for both SurePath and ThinPrep.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Microbiology
Vol/bind54
Udgave nummer9
Sider (fra-til)2267-2272
ISSN0095-1137
DOI
StatusUdgivet - okt. 2016

ID: 46521619